Trials / Recruiting
RecruitingNCT06663358
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegunigalsidase-alfa | Administered via intravenous (IV) infusion under conditions of routine clinical care |
Timeline
- Start date
- 2024-11-06
- Primary completion
- 2029-11-01
- Completion
- 2029-11-01
- First posted
- 2024-10-29
- Last updated
- 2025-11-14
Locations
10 sites across 3 countries: United States, Slovenia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06663358. Inclusion in this directory is not an endorsement.